Skip to main content
Theralase Technologies Inc. logo

Theralase Technologies Inc. — Investor Relations & Filings

Ticker · TLT ISIN · CA88337V1004 LEI · 529900NI3Y8GLE2IBF28 TSXV Manufacturing
Open in API
Filings indexed 698 across all filing types
Latest filing 2026-02-02 Regulatory Filings
Country CA Canada
Listing TSXV TLT

About Theralase Technologies Inc.

https://theralase.com/

Theralase Technologies Inc. designs, develops, manufactures, and markets patented laser technology platforms for both bio-stimulative and bio-destructive medical applications. The company operates two core divisions. The first is Cool Laser Therapy (CLT), which utilizes proprietary super-pulsed laser systems for therapeutic purposes, focusing on pain management, inflammation reduction, tissue repair, and the effective elimination of chronic knee pain. The second is Anti-Cancer Therapy (ACT), which employs patented light-activated Photo Dynamic Compounds (PDCs) combined with laser technology for destructive applications, specifically targeting the safe and effective destruction of cancer, bacteria, and viruses.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release issued by Theralase Technologies Inc. announcing the completion of patient enrollment for a Phase II clinical study. It follows the standard format of a corporate news release, including forward-looking statements, contact information, and a disclaimer regarding the TSX Venture Exchange. Since it does not fit into specific categories like financial reports, board changes, or dividend announcements, and serves as a general corporate update/announcement, it is classified as a Regulatory Filing (RNS).
2026-02-02 English
Material change report - English.pdf
Regulatory Filings Classification · 95% confidence The document is a 'Material Change Report' (Form 51-102F3) filed by Theralase Technologies Inc. in accordance with Canadian securities regulations. It details a specific corporate event—the entry into a Clinical Development Agreement with Ferring Pharmaceuticals—and includes the associated press release as an attachment. Since this is a formal regulatory filing documenting a material change in the company's business operations, it falls under the 'Regulatory Filings' category.
2026-01-27 English
Material document(s).pdf
Regulatory Filings Classification · 95% confidence The document is a legal contract titled 'Theralase® - Ferring Clinical Study Agreement'. It outlines the terms, definitions, and responsibilities between two pharmaceutical companies regarding a clinical study. It does not contain financial statements, earnings results, or shareholder voting information. As it is a legal agreement/contract that does not fit into the specific financial reporting categories, it falls under the 'Regulatory Filings' (RNS) category as the appropriate fallback for miscellaneous corporate filings.
2026-01-27 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing a collaborative clinical development agreement between Ferring Pharmaceuticals and Theralase Technologies. It details the nature of the partnership, the specific drugs involved (ADSTILADRIN and Ruvidar), and the clinical study objectives. It follows the standard format of a corporate press release, including forward-looking statements and contact information. Since it does not fit into specific financial reporting categories like 10-K, IR, or ER, and is not a report publication announcement (as it is the primary announcement itself), it is classified as a general regulatory filing/announcement.
2026-01-12 English
Material change report - English.pdf
Capital/Financing Update Classification · 98% confidence The document is a 'Material Change Report' (Form 51-102F3) filed by Theralase Technologies Inc. in accordance with Canadian securities regulations. It details a specific corporate event—the closing of a non-brokered private placement (financing). While it includes a press release as an attachment, the primary document is a formal regulatory filing regarding a capital raise. According to the provided definitions, documents detailing fundraising and financing activities are classified as 'Capital/Financing Update' (CAP).
2026-01-08 English
Report of exempt distribution (45-106F1).pdf
Regulatory Filings Classification · 95% confidence The document is a 'Form 45-106F1 Report of Exempt Distribution', which is a standard Canadian regulatory filing used to report the distribution of securities under prospectus exemptions. This document details the issuer, the nature of the distribution (common shares and warrants), the jurisdictions involved, and compensation paid to underwriters. It does not fit into categories like Annual Reports, Earnings Releases, or Investor Presentations. As it is a specific regulatory filing required by Canadian securities commissions for capital raising activities, it falls under the 'Regulatory Filings' category.
2026-01-06 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.